AustriaAustria

Austria – more cash for vaccine designers

16.12.2011

Vienna – Two big investors have poured €25m into Austrian vaccine specialist Affiris AG. Venture fund Santo VC – the investment vehicle of German biotech investors Thomas and Andreas Strüngmann – donated €20m, while the German MIG Fonds expanded an existing investment in their MIG11 portfolio with a further €5m. Both investors secured an option for further capital injections that could end up totalling €30m. Affiris CSO und co-founder Frank Mattner said: “We knew from the start that all stakeholders share a common understanding of where the journey of Affiris should take us.”
On the basis of its proprietary Affitom Technology, Affiris is developing vaccines for several indications, among them ones for Alzheimer’s, Parkinson’s, atherosclerosis and high blood pressure. Up to now, Affiris has pocketed about €12m from MIG – the only out-of-house investor on board since the firm was founded. In 2008, British drugmaker GlaxoSmithKline acquired the rights to develop and commercialise two Alzheimer’s disease vaccine candidates that are based on Affiris‘ Affitope technology. These are currently in Phase I clinical development. The total potential value of the agreement could reach a430m. Last October, the Michael J. Fox Foundation announced that it was awarding €1.5m to Affiris for a clinical study of the Parkinson’s vaccine candidate Affitope PD01.

AustriaAustria

12.02.2010

Vienna – Austria-based Intercell AG yesterday announced that its first-in-man trial of the subunit vaccine IV47, designed to prevent infections from the majority of so Streptococcus pneumoniae serotypes, of which there are over...

AustriaAustria

01.02.2010

Vienna – Austrian-based biotech company f-star has closed an EUR8m extension to its Series A financing round. The investment was co-led by MP Healthcare Venture Management and Merck Serono Ventures. Existing investors Atlas...

AustriaAustria

01.02.2010

Vienna – With the naming of Beatrix Karl as the new Minister of Science, the Austrian government is complete. The 42 year-old legal scientist will follow pre­decessor Johannes Hahn, who has accepted a position as European...

AustriaAustria

01.02.2010

AustriaAustria

01.02.2010

Vienna – Austrian vaccine specialist Intercell and GlaxoSmithKline Biologicals SA (GSK) have formed a strategic alliance to commercialise needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine...

AustriaAustria

06.01.2010

Vienna – Austrian firm Intercell AG has initiated a phase II efficacy trial as part of its clinical development program for the investigational travellers’ diarrhoea (TD) vaccine in India. The primary objective of the field trial...

AustriaAustria

29.12.2009

Vienna – Austrian vaccine specialist Intercell AG is to expand the label of its vaccine Ixiaro/JEspect for Japanese encephalitis (JE). On Monday the company announced the start of a clinical phase III study for the travel...

Politics / Law, Miscellaneous, AustriaAustria

04.11.2009

Graz – Austria is likely to lead the EU’s efforts to integrate existing national biobanks and associated data throughout Europe into a European biobanking infrastructure. The resource is aimed at reaching critical mass for the...

AustriaAustria

21.09.2009

Vienna – Cardiovascular and inflammatory specialist Fibrex Medical has published positive Phase II results for FX06, a peptide for the treatment of reperfusion injury – damage to heart muscle that results from remedial treatment...

Politics / Law, AustriaAustria

14.07.2009

The cultivation of genetically modified organisms (GMOs) in the European Union could soon no longer be decided by scientific facts, but by political preferences. Fourteen member states – among them France, Poland and Portugal –...

Displaying results 31 to 40 out of 116

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/3/article/austria-more-cash-for-vaccine-designers.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues